Log In
BCIQ
Print this Print this
 

Gencaro, bucindolol

  Manage Alerts
Collapse Summary General Information
Company Arca biopharma Inc.
DescriptionNon-selective beta blocker and mild vasodilator
Molecular Target Adrenergic receptor beta (ADRB)
Mechanism of ActionAdrenergic receptor beta (ADRB) antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II/III
Standard IndicationFibrillation
Indication DetailsPrevent atrial fibrillation (AF); Prevent atrial fibrillation in patients with heart failure and left ventricular dysfunction who also have a specific genotype of the beta-1 adrenergic receptor; Prevent atrial fibrillation/atrial flutter in patients with reduced left ventricular ejection fraction (LVEF)
Regulatory Designation U.S. - Fast Track (Prevent atrial fibrillation/atrial flutter in patients with reduced left ventricular ejection fraction (LVEF))
PartnerAeolus Pharmaceuticals Inc.;
Bristol-Myers Squibb Co.;
Endo International plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/25/2011

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today